"Low Dose" Metformin Improves Hyperglycemia Better Than Acarbose in Type 2 Diabetics | Zendy

Ken Yajima | Zendy; Akira Shimada | Zendy; Hiroshi Hirose | Zendy; Akira Kasuga | Zendy; Takao Saruta | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

"Low Dose" Metformin Improves Hyperglycemia Better Than Acarbose in Type 2 Diabetics

Author(s) -

Ken Yajima,

Akira Shimada,

Hiroshi Hirose,

Akira Kasuga,

Takao Saruta

Publication year - 2004

Publication title -

the review of diabetic studies

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.701

H-Index - 41

eISSN - 1614-0575

pISSN - 1613-6071

DOI - 10.1900/rds.2004.1.89

Subject(s) - acarbose , metformin , medicine , glycemic , type 2 diabetes , endocrinology , body mass index , diabetes mellitus , glycemic index , obesity

"High dose" metformin therapy (2,550 mg/day) is reported to improve glycemic control in type 2 diabetic patients with obesity (body mass index (BMI) > or = 30). Some have reported that metformin therapy, even in low doses (500-750 mg/day), improves glycemic control in non-obese type 2 diabetic patients (BMI approximately 25). However, it is unclear whether "low dose" metformin improves glycemic control better than acarbose in non-obese type 2 diabetic patients, which has been shown to improve glycemic control in type 2 diabetes with obesity.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research